Latest / The Bell2Bell (B2B) Podcast

Bell2Bell Podcast featuring Longeveron Inc. CEO Wa’el Hashad
Bell2Bell’s latest podcast features Wa’el Hashad, CEO of Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty.
To begin the interview, Hashad introduced Longeveron and its business model.
“Longeveron is a cell therapy-based biotech company. It was established in 2014 as a spin-off from a technology that was developed at the University of Miami School of Medicine by a renowned scientist and…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.